Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
Abbott India's profit jumped 24.1 per cent to Rs 287.1 crore in the March quarter of FY24 (Q4FY24), from Rs 231.4 crore in the March quarter of FY23 (Q4FY23)
In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction
The DCGI has cautioned against the consumption of Abbott's antacid Digene gel citing safety concerns, even as the US-based drugmaker recalled several batches of the medicine manufactured at its Goa facility. According to a letter by the Drugs Controller General of India (DCGI), it was reported on August 9 that a bottle of Digene Gel (mint flavour), batch no 51030307, used by customers was of regular taste (sweet) and light pink in colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour as per a complaint. "Accordingly, M/s Abbott India Limited, Verna Industrial Estate, Salcette, Goa- vide letter dated August 11, 2023, informed DCGI office for voluntary recall of impugned product Digene Mint flavour batch no 51030307 and Digene Gel orange having batch no 50035107, 50035207, 50035307, 50035407 and voluntary stopped production of all variants of Digene Gel manufactured at their Goa facility," the DCGI letter stated. Further, Abbott India
Abbott's diagnostic sales came in at $2.3 billion in the quarter, in line with analysts' average estimates.
Thyronorm has no quality issue, mislabeled batch was invoiced in Madhya Pradesh and Telangana: Company
US 10-year Treasury yield at highest since July 2008; Netflix jumps after reversing customer losses; P&G, Travelers post upbeat earnings; PHLX Housing Index falls 3% on weak US housing data
Analysts expect double-digit growth for pharma major even if Q1 disappointed
TNMSC Managing Director Deepak Jacob said the step was taken after a complaint from Paris Legal Cell in Chennai
The Defense Production Act order requires suppliers of formula manufacturers to fulfil orders from those companies before other customers, in an effort to eliminate production bottlenecks
The shortage stems from a February recall by Abbott that exacerbated ongoing supply chain disruptions among formula makers, leaving fewer options on stores shelves across much of the country
Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care
The two leaders emphasised that enhanced economic cooperation between India and Australia would help the two countries
(Reuters) -Abbott Laboratories' quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical device sales.
Firm expects demand from both, institutions and retail consumers, will import kits in 4-pack sizes from Korean plant; Test linked with NAVICA app which uploads results on ICMR website
The device is particularly useful for tiny babies who may not be able to undergo surgery to repair their hearts
Abbott said it is already in the process of delivering antibody tests to leading government and private hospitals and labs across different states
In talks with Medtronic and Abbott on relocating units
The company had posted a profit of Rs 137.68 crore for the year-ago period, Abbott India said in a filing to BSE
Abbott may now join Indian Pharmaceuticals Alliance which represents domestic generic drug makers
Plans a second-generation variety of Absorb for the Indian market